Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
Want to see LXEO full AI Analyst Report?
Top Page
Lexeo Therapeutics, Inc.
(NASDAQ:LXEO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.50
▼(-34.88% Downside)
Action:Reiterated
Date:06/15/26
The score is held down primarily by weak financial performance (minimal revenue, large losses, and deep negative free cash flow) and bearish technicals (below key moving averages with negative MACD). Positive corporate milestones around the pivotal LX2006 program and a low-debt balance sheet provide partial support, but do not fully offset the ongoing burn and downtrend.
Positive Factors
Regulatory / Clinical Pathway Progress
Finalizing the SUNRISE-FA 2 protocol and an FDA-acknowledged accelerated approval pathway materially de-risks development timing and regulatory clarity. This durable milestone narrows the path to a BLA, sets explicit readout timelines and reduces program execution uncertainty over the next 2–3 years.
Negative Factors
High Cash Burn
Sustained negative operating and free cash flow near -$99M TTM signals structural cash burn typical of development-stage biotechs. Persistent burn erodes runway if clinical timelines slip, increasing dependency on external financing and dilutive raises that can constrain long-term strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory / Clinical Pathway Progress
Finalizing the SUNRISE-FA 2 protocol and an FDA-acknowledged accelerated approval pathway materially de-risks development timing and regulatory clarity. This durable milestone narrows the path to a BLA, sets explicit readout timelines and reduces program execution uncertainty over the next 2–3 years.
Read all positive factors
Lexeo Therapeutics, Inc. (LXEO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$372.98M
Dividend YieldN/A
Average Volume (3M)777.34K
Price to Earnings (P/E)―
Beta (1Y)2.22
Revenue GrowthN/A
EPS Growth56.00%
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.45
Shares Outstanding78,521,640
10 Day Avg. Volume746,031
30 Day Avg. Volume777,336
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.16
Price to Sales (P/S)0.00
P/FCF Ratio-5.38
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-598.23
Enterprise Value/Ebitda-3.83
Forecast
1Y Price Target
$18.60Price Target Upside169.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.17
Revenue Forecast (FY)N/A
Lexeo Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX...
How the Company Makes Money
null...
Lexeo Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 654.00K | 1.66M |
| Gross Profit | -546.00K | 0.00 | 0.00 | 0.00 | 654.00K | 1.66M |
| EBITDA | -85.19M | -97.68M | -96.19M | -64.35M | -58.04M | -50.61M |
| Net Income | -87.50M | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M |
Balance Sheet | ||||||
| Total Assets | 250.36M | 268.69M | 146.94M | 139.81M | 97.08M | 136.86M |
| Cash, Cash Equivalents and Short-Term Investments | 71.77M | 181.77M | 121.52M | 121.47M | 77.33M | 135.86M |
| Total Debt | 7.37M | 7.89M | 9.92M | 11.64M | 13.48M | 0.00 |
| Total Liabilities | 18.86M | 22.02M | 30.10M | 26.27M | 210.03M | 192.46M |
| Stockholders Equity | 231.50M | 246.67M | 116.84M | 113.53M | -112.95M | -55.60M |
Cash Flow | ||||||
| Free Cash Flow | -98.42M | -98.96M | -81.63M | -59.66M | -55.46M | -44.37M |
| Operating Cash Flow | -97.99M | -98.56M | -81.15M | -59.50M | -54.56M | -44.18M |
| Investing Cash Flow | -78.39M | -90.25M | -94.08M | -165.00K | -901.00K | -188.00K |
| Financing Cash Flow | 219.24M | 216.79M | 88.78M | 103.79M | 189.00K | 150.86M |
Lexeo Therapeutics, Inc. Technical Analysis
Neutral
6.91
Price Trends
5.46
Negative
6.03
Negative
7.14
Negative
Market Momentum
-0.24
Negative
51.97
Neutral
69.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXEO, the sentiment is Neutral. The current price of 6.91 is above the 20-day moving average (MA) of 4.72, above the 50-day MA of 5.46, and below the 200-day MA of 7.14, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 51.97 is Neutral, neither overbought nor oversold. The STOCH value of 69.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LXEO.
Lexeo Therapeutics, Inc. Risk Analysis
Lexeo Therapeutics, Inc. disclosed 75 risk factors in its most recent earnings report. Lexeo Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lexeo Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.51B | -14.01 | -59.27% | ― | -100.00% | -62.96% | |
48 Neutral | $306.60M | -8.78 | -77.09% | ― | ― | -9.22% | |
47 Neutral | $353.20M | -1.82 | -134.14% | ― | ― | -39.31% | |
46 Neutral | $372.98M | -4.62 | -47.48% | ― | ― | 56.00% | |
44 Neutral | $381.33M | ― | -34.82% | ― | ― | 41.21% | |
42 Neutral | $24.67M | -1.57 | -64.17% | ― | -100.00% | 94.65% |
* Healthcare Sector Average
LXEO
Lexeo Therapeutics, Inc.
4.98
0.74
17.45%
TVRD
Tvardi Therapeutics
2.58
-23.01
-89.92%
LRMR
Larimar Therapeutics
3.54
0.80
29.20%
CAPR
Capricor Therapeutics
27.95
16.01
134.09%
BNTC
Benitec Biopharma
11.80
-3.14
-21.02%
DMAC
Diamedica Therapeutics
5.73
1.91
50.00%
Lexeo Therapeutics, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Lexeo Advances Pivotal LX2006 Trial for FA Cardiomyopathy
Positive
Jun 15, 2026
On June 15, 2026, Lexeo Therapeutics announced it has finalized the pivotal SUNRISE-FA 2 trial protocol and statistical analysis plan for LX2006, its gene therapy candidate for Friedreich ataxia cardiomyopathy, aiming to support a future Biologics...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresProduct-Related AnnouncementsRegulatory Filings and Compliance
Lexeo Highlights Q1 Progress Advancing Cardiac Gene Therapies
Positive
May 11, 2026
On May 11, 2026, Lexeo Therapeutics reported first-quarter 2026 results and operational progress, highlighting advancement of its LX2006 and LX2020 gene therapy programs and strengthening of its leadership. The company submitted the SUNRISE-FA2 pi...
Business Operations and StrategyExecutive/Board Changes
Lexeo Therapeutics Adds Genomic Medicine Leader to Board
Positive
Apr 30, 2026
On April 28, 2026, Lexeo Therapeutics appointed Dr. Laura Sepp-Lorenzino to its board of directors, with her term running through the 2028 annual meeting of stockholders. She was also named to the Science and Technology Committee, reinforcing the ...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances
Positive
Mar 30, 2026
Lexeo Therapeutics reported fourth-quarter and full-year 2025 results on March 30, 2026, highlighting steady advancement of its cardiac gene therapy pipeline and a strengthened balance sheet. The company ended 2025 with $246.6 million in cash, cas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.